ClinicalTrials.Veeva
Menu

Find clinical trials for Non-Small-Cell Lung Cancer in Nashville, TN

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Non-Small-Cell Lung Carcinoma
Lung Cancer
Cancer
Carcinoma
Squamous Cell Carcinoma of Head and Neck
Colorectal Cancer
Triple Negative Breast Cancer

Non-Small-Cell Lung Cancer trials near Nashville, TN, USA:

Study to Evaluate Monotherapy and Combination Immunotherapies in Participants With PD-L1 Positive Non-small Cell Lung Cancer (ARC-7)

with zimberelimab, and domvanalimab in combination with zimberelimab and etrumadenant (AB928) in front-line, PD-L1 positive, metastatic non- ...

Active, not recruiting
Squamous Non Small Cell Lung Cancer
Nonsquamous Non Small Cell Lung Cancer
Drug: Zimberelimab
Drug: Domvanalimab

Phase 2

Arcus Biosciences
Arcus Biosciences

Nashville, Tennessee, United States and 64 other locations

This study was designed to evaluate the safety and efficacy of trastuzumab deruxtecan in HER2-mutated metastatic non-small cell...

Active, not recruiting
Non-Small Cell Lung Cancer
Drug: Trastuzumab deruxtecan

Phase 2

Daiichi Sankyo
Daiichi Sankyo

Nashville, Tennessee, United States and 47 other locations

This is a study of the efficacy, pharmacokinetics, and safety of DS-1062a in participants with advanced or metastatic non-small cell...

Active, not recruiting
Non-small Cell Lung Cancer
Drug: DS-1062a

Phase 2

Daiichi Sankyo
Daiichi Sankyo

Nashville, Tennessee, United States and 83 other locations

, HER3-DXd will be evaluated in participants with metastatic or unresectable NSCLC with EGFR activating mutation or squamous or non-squamous...

Enrolling
Non-Small Cell Lung Cancer (NSCLC)
Drug: HER3-DXd (CTM-1 Lyo-DP)
Drug: HER3-DXd (CTM-3 Lyo-DP)

Phase 1

Daiichi Sankyo
Daiichi Sankyo

Nashville, Tennessee, United States and 21 other locations

The purpose of this study is to assess the objective response rate (ORR) of immunotherapy-based combination therapy and to assess the safety and tole...

Enrolling
Advanced Non-Small Cell Lung Cancer
Drug: Docetaxel
Drug: Platinum-Based Doublet

Phase 2

Arcus Biosciences
Arcus Biosciences

Nashville, Tennessee, United States and 29 other locations

in participants with previously treated advanced or metastatic non-small cell lung cancer (NSCLC) with o...

Active, not recruiting
Non-small Cell Lung Cancer
Drug: DS-1062a
Drug: Docetaxel

Phase 3

Daiichi Sankyo
Daiichi Sankyo

Nashville, Tennessee, United States and 205 other locations

A study to assess the Effects of MEDI4736 (Durvalumab) in Patients With Locally Advanced or Metastatic Non Small Cell Lung...

Active, not recruiting
Non-Small Cell Lung Cancer
Drug: MEDI4736

Phase 2

AstraZeneca
AstraZeneca

Nashville, Tennessee, United States and 137 other locations

This study is designed to evaluate the antitumor activity of patritumab deruxtecan in participants with metastatic or locally advanced NSCLC with an...

Active, not recruiting
Non-Small Cell Lung Cancer Metastatic
Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor
Drug: Patritumab Deruxtecan (Fixed dose)
Drug: Patritumab Deruxtecan (Up-Titration)

Phase 2

Daiichi Sankyo
Daiichi Sankyo

Nashville, Tennessee, United States and 123 other locations

This is an open-label, multicenter, non-randomized, Phase 2 study to determine the safety, tolerability and efficacy of encorafenib given in-...

Active, not recruiting
Non-small Cell Lung Cancer
Drug: encorafenib
Drug: binimetinib

Phase 2

Pfizer
Pfizer

Nashville, Tennessee, United States and 156 other locations

This study is being done to determine the efficacy and safety of cofetuzumab pelidotin in the PTK7-expressing, recurrent non-small ...

Active, not recruiting
Non-small Cell Lung Cancer (NSCLC)
Cancer
Drug: Cofetuzumab Pelidotin

Phase 1

AbbVie
AbbVie

Nashville, Tennessee, United States and 25 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems